

OGT expands SureSeq NGS portfolio

April 13, 2020—[Oxford Gene Technology](#) has added detection capabilities for translocations and difficult-to-sequence partial tandem duplications in its MyPanel customizable SureSeq NGS panels. The expanded content enables OGT SureSeq MyPanel custom panels to be customized to include the *BCR-ABL* gene fusion, resulting from a translocation of chromosome 9 and 22 generating the Philadelphia chromosome. OGT's Interpret software can detect translocation events in the genome and agnostically screen for split reads. Partial tandem duplications in acute myeloid leukemia can also be detected, including those in the *KMT2A (MLL)* gene. Researchers can choose to customize content and include *KMT2A*-PTD detection.